Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Pembrolizumab: Rapidly moving the field forward through industry-academic collaborations
Date
10 Oct 2016Session
Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agentsPresenters
Paul HaluskaAuthors
P. HaluskaAuthor affiliations
- Global Center For Scientific Affairs, Merck, 07065 - Rahway/US
Resources
Login to access the resources on OncologyPRO.
If you do not have an ESMO account, please create one for free.
Resources from the same session
Introduction
Presenter: Roger Stupp
Session: Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Resources:
Slides
Developing drugs targeting the PI3K/AKT signalling
Presenter: Li Yan
Session: Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Resources:
Slides
Novel clinical trial designs incorporating genomics for developing anti-cancer drugs: Olaparib in prostate cancer
Presenter: Johann de Bono
Session: Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Resources:
Slides
The role of consortia and corporative groups in the modern era of cancer drug development
Presenter: Roger Stupp
Session: Transforming academia-industry partnerships to expedite clinical development of innovative anti-cancer agents
Resources:
Slides
This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.
For more detailed information on the cookies we use, please check our Privacy Policy.
-
Necessary cookies enable core functionality. The website cannot function properly without these cookies, and can only be disabled by changing your browser preferences.